Abstract Details

Title Evaluation of Drug-Drug Interactions between VX-765 and Common Anti-Epileptic Medications in Subjects with Treatment-Resistant Partial-Onset Epilepsy

Topic Epilepsy

Presentation(s) IN9 - (-)

Poster/Presentation
Number 002

Objective

Background Studies have shown that the interleukin 1 beta (IL-1?) signaling pathway mediates inflammatory responses that play an important role in establishing seizures and causing epilepsy. VX-765 is an investigational orally bioavailable pro-drug of a selective and reversible interleukin 1 beta-converting enzyme (ICE) inhibitor (VRT-043198) and is a novel therapeutic approach for subjects with treatment-resistant partial-onset epilepsy. Clinically, VX-765 would be commonly administered with anti-epileptic drugs (AEDs) which contain many cytochrome P450 inducers and substrates. Drug-drug interactions could potentially occur between VX-765 and AEDs, although in vitro studies showed that the cytochrome P450 enzyme system is unlikely to play a major role in VX-765 metabolism.

Design/Methods In this phase 2a study, VX-765 was co-administered (900 mg 3 times per day for 6 weeks) with 1 to 4 concomitant AEDs to 48 subjects with treatment-resistant partial-onset epilepsy. Concentrations of VX-765 one hour post-dose alone with trough concentrations on Day 1 and Day 28 were compared with historic data in which the same dose of VX-765 was given to healthy subjects. In addition, bioequivalence tests were conducted to compare the trough concentrations of AEDs at baseline and in the treatment period (with VX-765 co-administered).

Results There were no substantial differences in VX-765 and VRT-043198 concentrations between the current study and historic data, indicating that VX-765 and VRT-043198 were unlikely affected by co-administration with common AEDs. Although the study was not statistically powered for these effects, the bioequivalence tests showed no significant changes in AED concentrations before and after co-administration with VX-765. The results suggest that AED concentrations were not affected by either VX-765 or VRT-043198.

Conclusions These findings indicate that VX-765 has minimal potential for drug-drug interactions with commonly administered AEDs.

Authors/Disclosures
Yingxue Chen PRESENTER	No disclosure on file
Pankaj D. Mehta, PhD	No disclosure on file
	No disclosure on file
James F. Paskavitz, MD	No disclosure on file
	No disclosure on file
	No disclosure on file
Merit E. Cudkowicz, MD, MSC, FAAN (Massachusetts General Hospital)	Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for biogen. Dr. Cudkowicz has received personal compensation in the range of $0-$499 for serving as a Consultant for cytokinetics. Dr. Cudkowicz has received personal compensation in the range of $0-$499 for serving as a Consultant for immunitypharm. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for transposon. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Quralis. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Regeneron. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for vectorY. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for inflectis. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for novartis. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ono. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for otsuka. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for coya. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ac immune. Dr. Cudkowicz has received personal compensation in the range of $0-$499 for serving as a Consultant for pontifax. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Inflectis. Dr. Cudkowicz has received personal compensation in the range of $0-$499 for serving as a Consultant for ab science. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for aclipse. Dr. Cudkowicz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Locust Walk. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pasithea. Dr. Cudkowicz has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Praxis Precision Medicine. Dr. Cudkowicz has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of Neurology . The institution of Dr. Cudkowicz has received research support from NINDS. The institution of Dr. Cudkowicz has received research support from ALSFAC. The institution of Dr. Cudkowicz has received research support from UCB ra. The institution of Dr. Cudkowicz has received research support from Biohaven. The institution of Dr. Cudkowicz has received research support from Clene nanomedicine. The institution of Dr. Cudkowicz has received research support from prilenia. The institution of Dr. Cudkowicz has received research support from ALS one. The institution of Dr. Cudkowicz has received research support from Seelos. The institution of Dr. Cudkowicz has received research support from Calico. The institution of Dr. Cudkowicz has received research support from denali. The institution of Dr. Cudkowicz has received research support from ITB. The institution of Dr. Cudkowicz has received research support from PharmAust. The institution of Dr. Cudkowicz has received research support from woolsley. Dr. Cudkowicz has received research support from lilly. The institution of Dr. Cudkowicz has received research support from J& J. Dr. Cudkowicz has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��